Earnings Call · Q2 FY2025·2025-08-07

Q2 25EPS +10.81%·Rev n/aQ1 25EPS +8.70%·Rev n/aQ4 24EPS +15.91%·Rev n/aQ3 24EPS -18.42%·Rev n/a⚠ consensus missing

Neumora Therapeutics, Inc. NMRA

Helen Rubinstein — Vice President of Investor Relations and Communications

Paul L. Berns — Chief Executive Officer

Joshua Pinto — Executive or Senior Management (likely Chief Scientific Officer or similar)

Chief Operationg & Development officer — Chief Operating & Development Officer

Michael Lee Milligan — Chief Financial Officer

+3.8%1d on move date+3.9% vs SPY3d−9.4%5d−1.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NMRA calls or request research access.

More NMRA calls Browse calls Request research access